Johnson & Johnson Reports real-world evidence Data for Lecanemab in Multiple myeloma

Johnson & Johnson today announced real-world evidence results for Lecanemab in patients with Multiple myeloma. The study demonstrated that Lecanemab demonstrates durable complete remissions compared to standard of care or placebo. These results provide important insights into the treatment of Multiple myeloma and support the continued development of Lecanemab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Lecanemab was consistent with previous observations, with no new safety signals identified.